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Abstract 
This study aimed to determine the interrater and intrarater reliability and agreement and 
the minimal detectable change (MDC) of the Timed Up & Go (TUG) test and the 10-
Meter Walk Test (10MWT) in older patients with Chronic Obstructive Pulmonary 
Disease (COPD). Patients (≥60 years old) living in the community were asked to attend 
2 sessions with 48-72h interval. In session 1, participants completed the TUG and 
10MWT twice (2 trials) and were assessed by 2 raters. In session 2, they repeated the 
tests twice and were assessed by 1 rater. Interrater and intrarater reliability were 
calculated for the exact scores (using data from trial 1) and mean scores (mean of 2 
trials) using Intraclass Correlation Coefficients (ICC2,1 and ICC2,2, respectively).  
Interrater and intrarater agreement were explored with the Bland & Altman method. The 
MDC95 was calculated from the standard error of measurement.  
Sixty participants (72.43±6.90 years old) completed session 1 and 41 participants 
session 2. Excellent ICC values were found for the TUG test (interrater: ICC2,1=0.997 
ICC2,2=0.999; intrarater: ICC2,1=0.921 ICC2,2=0.964) and 10MWT (interrater: 
ICC2,1=0.992 ICC2,2=0.997; intrarater: ICC2,1=0.903 ICC2,2=0.946). Good interrater and 
intrarater agreement was also found for both tests. The MDC95 was 2.68s and 1.84s for 
the TUG and 0.40m/s and 0.30m/s for the 10MWT considering the exact and mean 
scores, respectively. Findings suggest that the TUG test and the 10MWT are reliable 
and have acceptable measurement error. Therefore, these measures may be used to 
assess functional balance (TUG) and gait (10MWT) deficits in older patients with 
COPD. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is one of the most prevalent chronic 
diseases among adults aged 60 and older [1] with systemic manifestations that can 
contribute to functional performance decline [2]. Impairments such as peripheral 
skeletal muscle dysfunction and reduced exercise capacity are well-documented 
systemic manifestations in patients with COPD [3]. Poor balance and slow gait speeds 
have also been described in these patients [4-9]. As a result, patients with COPD may 
experience difficulties in performing daily life activities that require functional mobility 
and balance control (e.g., moving around, dressing) [6] and be at higher risk of falling 
[4]. 
To manage and monitor balance and gait speed deficits in research and clinical settings, 
clinicians should routinely measure these parameters in patients with COPD. For this 
purpose, they need simple and reliable measures that can easily be applied in the clinical 
context and reflect true changes over time or in response to interventions. Several 
clinical measures have been developed to assess balance and gait deficits in older adults, 
such as the Timed Up & Go (TUG) test [10] and the 10-Meter Walk Test (10MWT) 
[11-13]. These are quick and easy-to-administer measures that do not require special 
equipment or space, being suitable to be applied in most clinical settings such as home 
care, (sub)acute rehabilitation facilities or long-term care facilities. The TUG test [10] is 
frequently used to assess functional balance, mobility skills and fall risk of older people 
[14, 15] and has been increasingly used in patients with COPD [4-7, 16, 17]. It 
incorporates a series of tasks necessary for independent living, such as walking, turning 
and sitting [18], thus providing a comprehensive representation of balance and 
functional mobility capacities of an individual. Another practical measure to assess 
functional mobility is the 10MWT [11-13]. This test assesses the short-duration gait 
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speed [19, 20] and has been widely used for measuring walking ability of patients with 
neurologic impairment [13, 21]. Recent studies have demonstrated that gait speed is 
related to a number of clinical outcomes in COPD [8, 9]. However, studies employing 
the 10MWT in patients with COPD are limited [22]. As this is a simple and quick 
measure that can be used in different settings (e.g., home-based, community-based), 
where space and time are not easily available, the 10MWT may provide relevant 
information in routine assessments of patients with COPD.  
Measurement properties of these clinical measures, such as interrater and intrarater 
reliability, have been studied in specific populations [23-27] but they have been scarcely 
examined in patients with COPD [22, 28]. Specifically, Mesquita et al. [28] assessed the 
within-day reliability of the TUG test in older patients with advanced grades of COPD, 
and Rozenberg et al. [22] assessed the within-day and between-days reliability and the 
construct validity of the usual and fast walking speeds using one version of the 10MWT 
in the same population. Therefore, further research is needed to assess the intrarater but 
also the interrater reliability in patients at all COPD grades. This is fundamental to 
determine the proportion of variance obtained in measurements conducted by different 
raters and/or under similar assessment conditions and to define to what extent the 
changes observed in a patient’s balance and gait scores are significant or associated with 
measurement error [29]. Therefore, the purpose of this study was to determine the 
interrater and intrarater reliability and agreement and the minimal detectable change 
(MDC) of the TUG test and the 10MWT in older patients with COPD. Knowing the 
measurement properties and associated measurement error of these simple tests is 
crucial before their widespread use in the clinical management of these patients. 
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Methods 
Study design  
A reliability and agreement study was conducted. Ethical approval was obtained from 
the Central Regional Health Administration and the Hospital Center of Baixo Vouga. 
This study was described following the guidelines for reporting reliability and 
agreement studies (GRRAS) [29]. 
 
Participants 
Patients with COPD were recruited from 2 primary care centers and 1 district hospital, 
from November 2012 to February 2013. Patients were identified by the physicians of 
the institutions, who ensured the fulfillment of eligibility criteria. Patients were included 
if they were: i) ≥60 years old; ii) diagnosed with COPD according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [30]; iii) living in the 
community; iv) clinically stable (no hospital admissions or exacerbations) for 1 month 
prior to the study; v) able to ambulate with or without a walking aid (but without the 
assistance of another person); and vi) able to follow simple instructions. Patients were 
excluded if they had severe musculoskeletal (e.g., severe osteoarthritis), neurological 
(e.g., Parkinson's disease), cardiovascular (e.g., stroke) or psychiatric (e.g., dementia) 
conditions/disorders and/or severe auditory/visual impairments that could interfere with 
the measurements.  
Patients were informed by their physicians about the study and asked about their 
willingness to participate. Patients who agreed to participate were contacted by the 
researchers to schedule an appointment. The written informed consent was obtained 
before data collection. 
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Data collection 
Participants were asked to attend 2 testing sessions with a 4872h interval.  
In the first session, patients completed a questionnaire with sociodemographic (age, 
gender) and health-related (smoking status, incidence of ≥1 falls in the preceding year, 
use of walking aids) information. Level of dyspnea was collected using the modified 
Medical Research Council (mMRC) dyspnea scale [31]. Height and weight were 
recorded to calculate the body mass index (BMI). Lung function was assessed with a 
portable spirometer (MicroLab 3500, CareFusion, Kent, UK) according to the 
guidelines [32]. This device uses the reference equations for lung function as defined in 
Quanjer et al. [33]. COPD severity was determined using the GOLD criteria [30]. 
Participants performed the TUG test and 10MWT twice in each testing session. Two 
previously trained clinicians with experience in applying these tests collected the data. 
Both raters evaluated the 2 trials of the TUG and 10MWT conducted in the first session 
to enable assessing interrater reliability. In the second session, only 1 of the raters 
evaluated 2 trials for further assessment of intrarater reliability. Prior to testing, 
participants received specific instructions on how to perform the tests and took a 
practice trial. Participants were encouraged to rest between trials, as needed. Effort was 
made to keep all factors associated with the testing sessions consistent, specifically the 
time of day, area in which the tests were performed, order of testing and use of a 
walking aid (if needed). No verbal encouragement was given during the tests. A random 
number generator was used to randomly assign the sequence of data collection (simple 
randomization).  
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Measures 
The TUG test [10] was performed in a corridor with a 3-meter mark on the floor 
(identified with adhesive tape) and a chair without armrests properly placed and fixed at 
the beginning mark. Instructions given to participants were as follow: when given the 
initiation word “Go”, they should rise from a chair, walk 3 meters as quickly and as 
safely as possible, turn around, return to the chair, and sit down with their back leaning 
against the backrest [34]. The fast TUG has been used in COPD [6, 7, 16, 17] and has 
been related to a higher risk of falls in community-dwelling older adults [15]. The time 
(seconds [s]) needed to perform the entire sequence was recorded using a stopwatch.  
The 10MWT [11-13] was used to assess gait speed. Although this test is known as the 
10MWT, gait speed is actually measured over 6 meters. The test was conducted in a 
corridor with 2 marks on the floor (identified with adhesive tape) denoting the 2 ends of 
a 10-meter walkway and another 2 marks identifying the 2 and 8 meters. Specific verbal 
instructions were given prior to the test: “I will say: ready, set, go. When I say ‘Go’, 
walk as fast as you safely can until I say stop”. Participants walked for 10 meters (m) at 
their fastest speed and the time for the intermediate 6 meters was measured to allow for 
acceleration and deceleration, starting when toes of the leading foot crossed the 2-meter 
mark and stopping when toes of the leading foot crossed the 8-meter mark. Maximum 
gait speed was used since a previous study has found that maximum speed declines 
more steeply than comfortable speed with increasing age and lower extremity muscle 
strength [11]. Gait speed (m/s) was calculated by dividing the distance walked on each 
trial (6m) by the time (s) required to complete the trial. 
In both tests, participants who used a walking aid on a daily basis were asked to use it 
during the tests.  
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Data analysis 
Statistical analyzes were conduced using SPSS version 22 (IBM Corp., Armonk, NY). 
Descriptive statistics were used to characterize the sample and to provide the scores of 
each test. Sociodemographic and health-related characteristics were compared between 
patients who completed the 2 testing sessions and those who failed to attend the second 
session, using independent t-tests for normally distributed data, Mann-Whitney U-tests 
for non-normally distributed and ordinal data and Chi-square tests for categorical data. 
Level of significance was set at 0.05.  
Relative reliability was assessed for the TUG test and 10MWT using the Intraclass 
Correlation Coefficient (ICC). Interrater reliability was computed using the scores 
obtained from the 2 raters in session 1 and intrarater reliability using the scores from 1 
rater in sessions 1 and 2. The ICC2,1 was computed for the exact scores using the scores 
from trial 1 and ICC2,2 for the mean scores of 2 trials [35]. Mean scores were used in 
addition to the exact scores since they are considered better estimates of true scores and 
can provide better reliability estimates [36]. This methodology has been used in other 
reliability studies [26, 37]. The ICC ranges from 0 to 1 and ‘good’ to ‘excellent’ 
reliability can be considered for ICC>0.75 [35]. However, to consider a measurement 
suitable for clinical use, ICC values should exceed 0.9 [29]. The 95% confidence 
intervals (95%CI) were also computed.  
The 95% limits of agreement (LoA) using the Bland & Altman plots [38] were 
performed to assess agreement between raters (interrater reliability) and sessions 
(intrarater reliability). The presence/absense of systematic error (e.g., due to learning 
effects or fatigue) between within-day trials was also assessed through the paired 
student t-test and the LoA, using the trials 1 and 2 of session 1 measured by one rater. 
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To assess absolute reliability, the standard error of measurement (SEM) was calculated 
for the TUG and 10MWT using scores obtained by 1 rater in sessions 1 and 2. The SEM 
indicates the extent to which a score varies on repeated measurements [39] and was 
calculated using the equation 1: 
𝑆𝐸𝑀 = 𝑆𝐷 ඥ(1 − 𝐼𝐶𝐶) (1) 
where SD is the standard deviation of the scores obtained from all individuals and ICC 
is the intrarater reliability coefficient. SEM was also expressed as a percentage of the 
mean (SEM%), which is independent of the units of measurement, defined as (equation 
2): 
𝑆𝐸𝑀% = (𝑆𝐸𝑀 𝑚𝑒𝑎𝑛) × 100⁄  (2) 
where mean is the mean of all scores obtained in sessions 1 and 2. The SEM (absolute 
value) was also used to determine the MDC, which is the smallest change in a patient’s 
score which indicates a true change in patient’s performance rather than the result of 
random measurement error. The MDC at the 95% level of confidence (MDC95) was 
calculated as follows (equation 3): 
𝑀𝐷𝐶ଽହ = 𝑆𝐸𝑀 × 1.96 × √2 (3) 
The MDC can also be expressed as a percentage (MDC%), defined as (equation 4): 
𝑀𝐷𝐶% = (𝑀𝐷𝐶ଽହ 𝑚𝑒𝑎𝑛) × 100⁄  (4) 
where mean is the mean of all scores obtained in the testing sessions. A MDC% below 
30% is considered acceptable [40]. 
 
Sample size 
Sample size was determined as described by Gwet [41] for interrater reliability studies, 
using the results from a previous pilot study (not published). Based on 2 raters, it was 
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determined that 60 patients would be necessary for an ICC of 0.9 and an expected 
95%CI length of 0.1. 
 
Results 
Participants 
Sixty-six patients were contacted and invited to participate in the study. However, 3 
refused to participate as they did not perceive the study as relevant and 3 were unable to 
attend the health center. Therefore, 60 patients (35 males) with a mean(±SD) age of 
72±7 years participated in the study. They had a BMI of 29±6kg/m2 and a FEV1 of 
65±23% of the predicted. Twenty five (42%) participants had fallen in the preceeding 
year. None of them used a walking aid. Participants’ characteristics are presented in 
Table 1. 
(table 1) 
From the 60 participants, 19 were lost to follow up due to unavailability to attend the 
health center (n=16) and respiratory exacerbations (n=3). Thus, 41 participants attended 
session 2. There were no significant differences between baseline characteristics of 
patients who completed the 2 testing sessions and the dropouts (p>0.05).  
 
Interrater reliability and agreement 
Scores of the TUG test and the 10MWT measured by 2 raters in session 1 and interrater 
reliability results are presented in Table 2. Results are shown for the exact scores and 
the mean scores. The ICCs for the interrater reliability were excellent on both tests, with 
the lower limit of the 95%CI being above 0.9 in both measures, either considering the 
exact scores (TUG: ICC2,1=0.997 95%CI 0.9950.998; 10MWT: ICC2,1=0.992 95%CI 
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0.9870.995) or the mean scores (TUG: ICC2,2=0.999 95%CI 0.9991; 10MWT: 
ICC2,2=0.997 95%CI 0.9950.998). 
(table 2) 
The Bland & Altman plots for the measures collected by the 2 raters are shown in 
Figure 1. Excelent agreement (i.e., the mean of the differences close to 0 and tight LoA) 
was found between raters for the TUG test and the 10MWT. No evidence of systematic 
bias was observed. 
(figure 1) 
 
Intrarater reliability, agreement and minimal detectable change (MDC95) 
Table 3 presents the scores of the TUG and 10MWT measured by the same rater in 
sessions 1 and 2 and intrarater reliability results. Intrarater reliability of TUG was 
excellent, with ICCs achieving the recommended value of 0.9. This was found for the 
exact scores (ICC2,1=0.921 95%CI 0.8550.957) and mean scores (ICC2,2=0.964 95%CI 
0.9310.981). Similar results were obtained for the 10MWT (exact scores: 
ICC2,1=0.903 95%CI 0.8260.947, p<0.001; mean scores: ICC2,2=0.946 95%CI 
0.8980.971, p<0.001). 
Good intrarater agreement results were found for both tests (Figure 2), with no evidence 
of systematic bias. 
(figure 2) 
No significant differences were found between trials of session 1 for the TUG test 
(8.94±3.23s vs. 8.79±3.21s, p=0.108) and the 10MWT (1.41±0.46m/s vs. 1.43±0.44m/s, 
p=0.107). The Bland & Altman plots showed no evidence of systematic error between 
within-day trials. 
(figure 3) 
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The SEM of the TUG test was 0.97s (SEM%=12.1) using exact scores and 0.66s 
(SEM%=8.4) using the mean scores, indicating a small variation in the measurement 
error. This test had a MDC95 of 2.68s (MDC%=33.5) and 1.84s (MDC%=23.2) for the 
exact and mean scores, respectively. 
Regarding the 10MWT, the SEM was 0.14m/s (SEM%=9.6) for the scores obtained in 
trial 1 and 0.11m/s (SEM%=7.1) for the mean scores of trials 1 and 2. The 10MWT also 
showed an acceptable measurement error, with a MDC95 of 0.40m/s (MDC%=26.5) for 
the exact scores and 0.30m/s (MDC%=19.6) for the mean scores. 
(table 3) 
   
Discussion 
This study evaluated the interrater and intrarater reliability and agreement of the TUG 
test and the 10MWT in older patients with COPD. These clinical measures showed 
excellent interrater and intrarater reliability, with ICC values exceeding the 
recommended 0.9 [29], and good agreement results. Estimates of measurement error 
(SEM, SEM%) and the minimal amount of change necessary to assume a meaningful 
change in patient’s performance (MDC95, MDC%) were relatively low for both 
measures. Findings suggest that the TUG test and the 10MWT are reliable measures to 
assess functional balance and gait deficits (respectively) in older patients with COPD.  
Excellent results were found for interrater and intrarater reliability of the TUG test 
(ICC>0.9). Similar results have been found in reliability studies conducted in other 
populations, such as Parkinson’s disease (interrater ICC=0.99;[42] intrarater ICC 0.80-
0.98) [40, 42], Alzheimer’s Disease (intrarater ICC=0.99) [26] and stroke (intrarater 
ICC=0.96) [43]. Regarding agreement and absolute reliability (SEM and MDC95) of the 
TUG, results were also encouraging since a small variation of measurement error was 
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found. A previous study conducted by Mesquita et al. [28] has also assessed the 
intrarater reliability and agreement parameters of the TUG test in patients with COPD. 
The authors found lower reliability and agreement results than those of the present study 
(first and second trials: ICC 0.85 95%CI 0.76–0.91; SEM=1.76; MDC95= 4.88, 
MDC%=43; for the Bland & Altman plots the reader is directed to the original article) 
[28]. However, comparison between the previous and the present studies should be done 
with caution since patients’ disease severity and the methodologies employed were 
different: disease severity (severe-to-very-severe COPD grades vs. all COPD grades, 
respectively), TUG pace (usual speed vs. fast speed), existence of a practice trial (no 
reference to a practice trial vs. existence of a practice trial), and time period between 
trials (within-day vs. between-day trials). As previously mentioned, the MDC95 
indicates the smallest real change of an outcome measure for a 95% confidence level. It 
should be noted that the MDC% of the TUG exact scores was slighty higher (33.5%) 
than the value considered aceptable (i.e., <30%) [40]. When the mean scores from the 2 
trials were considered, the MDC% decreased to 23.2% though. These findings suggest 
that, when using TUG scores in COPD, clinicians should calculate the average of 2 
measurements in order to reduce the magnitude of measurement error and thus be more 
confident that a real statistical change has occurred [36]. Nevertheless, further research 
is warranted before firm conclusions can be drawn. 
The MDC values of the TUG test obtained in the present study may be used by 
clinicians to identify a true statistical change (beyond measurement error) in a patient’s 
TUG score over time or in response to interventions. Previous studies using the TUG 
test to evaluate the effects of an intervention in patients with COPD have found pre-
posttest mean differences of -1.5s [44] and -1.7s [17], which are lower than the MDC 
values found in the present study (2.68s and 1.84s for the exact and mean scores, 
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respectively). This suggests that, on average, the interventions did not produce a true 
statistical change in patients’ TUG scores. Nevertheless, it is not known the proportion 
of patients achieving a degree of improvement that was beyond the MDC, which is a 
more informative method for describing the effects of the intervention than the overall 
mean change [45]. Further research is needed to clarify this issue. 
No evidence of systematic error was found for the TUG test between trials 1 and 2 
during session 1. Mesquita et al. [28] have found that trial 2 of the TUG test was 
significantly better than trial 1 (possibly due to learning effects) but there were no 
differences between trials 2 and 3. In the present study, a practice trial was allowed 
before trials 1 and 2, which may have corresponded to trial 1 of the study from 
Mesquita et al. [28], thereby supporting their results. 
The 10MWT also showed excellent (relative and absolute) reliability and good 
agreement in patients with COPD. It has been recognized that gait speed is an important 
functional measure which has been linked to fall risk [46], fear of falling [47] and 
survival [48] in older adults. It also predicts future functional decline [49, 50]. Hence, 
gait speed has been considered a “functional vital sign” [51]. Gait speed has not been 
extensively studied in COPD; nevertheless, recent studies have suggested that it can 
also be an indicator of functional decline in this population since it has been associated 
to patients’ symptoms (e.g., dyspnea, fatigue), exercise tolerance and quality of life [8, 
9]. As the 10MWT was found to be reliable in patients with COPD and may be applied 
in different settings, future studies should explore the value of gait speed measured by 
the 10MWT in assessing functional capacity of patients with COPD and its relationship 
with other clinical measures. 
In the present study, gait speed was calculated by considering the time needed to walk 
the intermediate 6 meters of the 10-meter course, to account for acceleration and 
Reliability and MDC of TUG and 10MWT in COPD 
15 
 
deceleration. However, a great variation exists in the literature concerning the distance 
[52, 53], testing protocol (e.g., presence/absence of specific distances for 
acceleration/deceleration) and pace (self-selected comfortable pace vs. fast pace) used 
[22, 52, 53]. Often, these testing parameters are chosen based more on tester preference 
and convenience, especially in some clinical settings where space is limited [54]. Thus, 
clinicians and researchers should clearly indicate which measurement method they have 
used in order to enable comparison among studies. Furthermore, the ICC, SEM and 
MDC95 of the present study should only be considered for studies using the same 
methodology and population. Unlike the TUG test, the MDC% of the the exact scores 
of the 10MWT was fairly below the value considered acceptable (MDC%=26.5). This 
suggests that a single measure may be sufficient to assess changes in patients’ gait 
speed without substantially increasing the measurement error. The non-significant 
results found for the differences between within-day trials further support these results, 
by suggesting that there was no evidence of systematic error. Further research is needed 
to support these findings. 
 
Limitations 
There are limitations in the present study that need to be acknowledged. Patients were 
60 years old or over and most of them had mild (n=20) and moderate (n=25) COPD, 
which may limit the generalizability of the findings to the all COPD population. Future 
studies should assess younger patients and use a more balanced sample of COPD 
grades. The number of participants lost to follow up was another limitation of the 
present study. Nevertheless, the characteristics of dropouts were similar to that of 
completers, thereby they might not have considerable influence in the reported results. 
Physiological measures, such as heart rate and peripheral oxygen saturation, were not 
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measured before and after each assessment, thus, it is currently unknown if the resting 
period was sufficient for patients to recover between trials. Another limitation concerns 
the use of the ICC. It is acknowledged that this reliability coefficient depends on the 
characteristics of the individuals included in the analysis: a large ICC can be found 
when the between-subjects variability is high, even if there is poor between-raters/trial-
to-trial variability; a low ICC can be found if the between-subjects variability is low, 
even when the between-raters/trial-to-trial variability is low [39]. Therefore, studies 
conducted in populations with different characteristics are likely to report ICC values 
different from the ones found in this study. For example, the lower ICC values found for 
the TUG test in the study of Mesquita et al. [28] may be attributable to the exclusive 
inclusion of patients at advanced grades of the disease (i.e., patients with similar 
characteristics). In the present study, all COPD grades were considered which may have 
lead to a great between-subjects variability and, thus, higher ICC results. Finally, 
measures used to calculate intrarater reliability were collected with a 4872h interval. 
This shorter reassessment interval was chosen since, in clinical practice (e.g., physical 
therapy), the period between visits is often smaller than 1 week. However, it is 
recognized that random measurement error is time-dependent and, thus, longer periods 
could lead to lower reliability values and higher measurement error [55]. Future studies 
could assess intrarater reliability of the TUG test and the 10MWT in various time 
intervals in order to study the effect of time (i.e., shorter vs. longer intervals) on 
measurement error. 
 
Conclusions 
This study showed that the TUG test and the 10MWT are highly reliable and have 
acceptable measurement error, thus they may be used to assess functional balance and 
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gait deficits (respectively) in older patients with COPD. Results also indicated that 
small improvements in test scores may be sufficient to detect true changes in a patient’s 
performance. These findings may help clinicians to interpret when a change corresponds 
to a true change (i.e., beyond measurement error) in a patient’s performance. 
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